These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35456040)

  • 1. Verteporfin Inhibits the Progression of Spontaneous Osteosarcoma Caused by Trp53 and Rb1 Deficiency in Ctsk-Expressing Cells via Impeding Hippo Pathway.
    Li Y; Yang S; Yang S
    Cells; 2022 Apr; 11(8):. PubMed ID: 35456040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma progression by activating glucose metabolism and YAP signaling.
    Li Y; Yang S; Liu Y; Yang S
    MedComm (2020); 2022 Jun; 3(2):e131. PubMed ID: 35615117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.
    Zucchini C; Manara MC; Cristalli C; Carrabotta M; Greco S; Pinca RS; Ferrari C; Landuzzi L; Pasello M; Lollini PL; Gambarotti M; Donati DM; Scotlandi K
    J Exp Clin Cancer Res; 2019 Dec; 38(1):503. PubMed ID: 31878963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice with Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma via overactivation of YAP signaling.
    Li Y; Yang S; Liu Y; Yang S
    Cell Death Dis; 2022 Jun; 13(6):570. PubMed ID: 35760773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
    Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
    Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.
    Luu AK; Schott CR; Jones R; Poon AC; Golding B; Hamed R; Deheshi B; Mutsaers A; Wood GA; Viloria-Petit AM
    BMC Vet Res; 2018 Nov; 14(1):365. PubMed ID: 30477496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
    Dong L; Lin F; Wu W; Liu Y; Huang W
    Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma.
    Quan Y; Li Z; Zhu K; Liang J
    Lipids Health Dis; 2021 Jul; 20(1):74. PubMed ID: 34304741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of angiotensin II activation of yes-associated protein/PDZ-binding motif signaling in hypertensive cardiac and vascular remodeling.
    Xu Q; Zhuo K; Zhang X; Zhen Y; Liu L; Zhang L; Gu Y; Jia H; Chen Q; Liu M; Dong J; Zhou MS
    Eur J Pharmacol; 2024 Jan; 962():176252. PubMed ID: 38061470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted inhibition of YAP/TAZ alters the biological behaviours of keloid fibroblasts.
    Gao N; Lu L; Ma X; Liu Z; Yang S; Han G
    Exp Dermatol; 2022 Mar; 31(3):320-329. PubMed ID: 34623712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the relationship of YAP and FAK in hMSCs and osteosarcoma cells: Discrimination of FAK modulation by nuclear YAP depletion or YAP silencing.
    Husari A; Steinberg T; Dieterle MP; Prucker O; Rühe J; Jung B; Tomakidi P
    Cell Signal; 2019 Nov; 63():109382. PubMed ID: 31376525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RGS12 is a novel tumor suppressor in osteosarcoma that inhibits YAP-TEAD1-Ezrin signaling.
    Li Y; Liu M; Yang S; Fuller AM; Karin Eisinger-Mathason TS; Yang S
    Oncogene; 2021 Apr; 40(14):2553-2566. PubMed ID: 33686240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLOD1, a target of miR-34c, contributes to cell growth and metastasis via repressing LATS1 phosphorylation and inactivating Hippo pathway in osteosarcoma.
    Wu X; Xiang H; Cong W; Yang H; Zhang G; Wang Y; Guo Z; Shen Y; Chen B
    Biochem Biophys Res Commun; 2020 Jun; 527(1):29-36. PubMed ID: 32446383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verteporfin induces apoptosis and reduces the stem cell-like properties in Neuroblastoma tumour-initiating cells through inhibition of the YAP/TAZ pathway.
    Fusco P; Mattiuzzo E; Frasson C; Viola G; Cimetta E; Esposito MR; Tonini GP
    Eur J Pharmacol; 2021 Feb; 893():173829. PubMed ID: 33347823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
    Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
    Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines.
    Ferraiuolo M; Pulito C; Finch-Edmondson M; Korita E; Maidecchi A; Donzelli S; Muti P; Serra M; Sudol M; Strano S; Blandino G
    Cancer Lett; 2018 Oct; 433():18-32. PubMed ID: 29933048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
    Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
    J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
    Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
    Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.